Sharechat Logo

Chorus submits 2022 fibre regulatory report

Wednesday 31st May 2023

Text too small?

Chorus has today published its Information Disclosure for fibre fixed lines access services (FFLAS) for the 2022 disclosure year. This disclosure will also be submitted to the Commerce Commission.

 

As part of this process Chorus has calculated that the regulated asset base (RAB) increased from $5,448 million to $5,710 million during 2022.

 

While annual RAB movements do not affect the maximum allowable revenue (MAR) in the current regulatory period, the RAB closing value will be the basis of the opening RAB for the next regulatory period from January 2025.

 

As expected, Chorus has calculated that it under-earnt its MAR for 2022. Revenues were $23 million lower than allowed in 2022 and, together with various other adjustments, this results in a wash-up balance of $47 million that will be carried forward to 2025.

 

Details of these calculations and other summary financial information are provided in the attached presentation summary.

 

All calculations are subject to Commerce Commission review and approval.

 

The full Information Disclosure reporting schedules are available at https://company.chorus.co.nz/disclosures

 

Authorised by:

 

Mark Aue

Chief Financial Officer

 

ENDS



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 30th Morning Report
December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK